Blood Ropivacaine level after PECS II block in patients undergoing mastectomy.

A prospective study of analgesic efficacy and plasma Ropivacaine concentration after PECS II block in patients undergoing mastectomy.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12617000261314

Enrollment

Registered

2017-02-20

Start date

2017-01-01

Completion date

2017-06-08

Last updated

2018-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

To measure the chronological changes in venous concentration of Ropivacaine after PECS II block, in which the calculation for the time point of maximum concentration of Ropivacaine occurred (Tmax) and maximum venous plama concentration (Cmax) are mandatory. This would determine whether the peak plasma Ropivacaine concentration level is within the safety level allowed. The venous threshold value of systemic toxicity is 2.2 microgram/ml. The result of this study might change future recommended dosing regimen for PECS II block practice using Ropivacaine.

Interventions

Venous blood will be sampled from the blood taking canulla at 0, 10, 20, 30, 45, 60, 90, and 120 minutes after PECS II block using Ropivacaine.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

adult female patients undergoing unilateral mastectomy with axillary clearance will be prospectively enrolled. Inclusion criteria: - ASA 1, 2 and 3 (without significant liver or renal impairment) - Age above 18 years old - Able to give consent - Body weight > 50kg

Exclusion criteria

- Patient’s refusal and inability to give consent or cooperation during procedure - Allergy or sensitivity to local anaesthetics - BMI>35

Outcome results